prof.dr. MJ (Maarten) IJzerman

Biography

Professor Maarten IJzerman is an internationally recognised leader in cancer health services research and biomedical innovation. Since May 2022, he serves as Dean of the Erasmus School of Health Policy & Management (ESHPM), where he also holds the position of Professor of Cancer Health Services Research. He leads a research program advancing genomics-enabled precision oncology and data-driven methods to optimise cancer care, with a focus on improving patient outcomes and healthcare sustainability. He is affiliated with Erasmus Medical Centre and a member of the Convergence Management Board (TU Delft, ErasmusMC and Erasmus University).

Maarten holds an honorary professor ship in the University of Melbourne and Peter MacCallum Cancer Centre. He previously held senior academic and leadership roles in Case School of Engineering (Cleveland OH, USA) and the International Society for Pharmacoeconomics and Outcomes Research (Philadelphia, USA).

His global research leadership includes serving as Principal or Co-Investigator in projects funded by the EU (Horizon, MSCA-ITN, COST), Australian NHMRC & MRFF, Canadian CIHR, Genome Canada, and the Netherlands NWO. He has contributed his expertise to high-level research evaluation panels for the European Commission (Horizon, Cancer Mission Board, Innovative Medicines/Health Initiative), and research evaluation panels in Australia, Singapore, Hong Kong and the United Kingdom.

Recognised in the top 2% of most cited scientists worldwide (Stanford–Elsevier), Maarten is a member of The Lancet Commission on Colorectal Cancer and, since January 2024, Chair of the Erasmus 2030 Strategy Steering Board shaping the Engaged University.

Maarten received a PhD in Biomedical Engineering (University of Twente) and an MSc in Biomedical Sciences (Radboud University Nijmegen). He is an INSEAD alumnus (International Directors Program, Singapore) and completed executive training in Health Economics (University of York) and Corporate Finance (Columbia University).

Beyond academia, he serves as a non-executive board member in the non-profit sector, valued for his ability to engage diverse teams, shape strategic vision, and drive health innovation on a global scale.